JP7668547B2 - 標的ｒｎａを編集する方法 - Google Patents

標的ｒｎａを編集する方法 Download PDF

Info

Publication number
JP7668547B2
JP7668547B2 JP2022512682A JP2022512682A JP7668547B2 JP 7668547 B2 JP7668547 B2 JP 7668547B2 JP 2022512682 A JP2022512682 A JP 2022512682A JP 2022512682 A JP2022512682 A JP 2022512682A JP 7668547 B2 JP7668547 B2 JP 7668547B2
Authority
JP
Japan
Prior art keywords
dyw
sequence
rna
amino acids
editing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022512682A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021201198A1 (https=
Inventor
瑞穂 一瀬
ベルナルド グットマン
祐介 八木
ゆみ 赤岩
恭香 島尻
崇裕 中村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EDITFORCE, INC.
Original Assignee
EDITFORCE, INC.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EDITFORCE, INC. filed Critical EDITFORCE, INC.
Publication of JPWO2021201198A1 publication Critical patent/JPWO2021201198A1/ja
Priority to JP2024065910A priority Critical patent/JP7698351B2/ja
Application granted granted Critical
Priority to JP2025073407A priority patent/JP7698371B1/ja
Publication of JP7668547B2 publication Critical patent/JP7668547B2/ja
Priority to JP2025094806A priority patent/JP2025120313A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022512682A 2020-03-31 2021-03-31 標的ｒｎａを編集する方法 Active JP7668547B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2024065910A JP7698351B2 (ja) 2020-03-31 2024-04-16 標的ｒｎａを編集する方法
JP2025073407A JP7698371B1 (ja) 2020-03-31 2025-04-25 標的ｒｎａを編集する方法
JP2025094806A JP2025120313A (ja) 2020-03-31 2025-06-06 標的ｒｎａを編集する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020065065 2020-03-31
JP2020065065 2020-03-31
PCT/JP2021/014096 WO2021201198A1 (ja) 2020-03-31 2021-03-31 標的ｒｎａを編集する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024065910A Division JP7698351B2 (ja) 2020-03-31 2024-04-16 標的ｒｎａを編集する方法

Publications (2)

Publication Number Publication Date
JPWO2021201198A1 JPWO2021201198A1 (https=) 2021-10-07
JP7668547B2 true JP7668547B2 (ja) 2025-04-25

Family

ID=77930108

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022512682A Active JP7668547B2 (ja) 2020-03-31 2021-03-31 標的ｒｎａを編集する方法
JP2024065910A Active JP7698351B2 (ja) 2020-03-31 2024-04-16 標的ｒｎａを編集する方法
JP2025073407A Active JP7698371B1 (ja) 2020-03-31 2025-04-25 標的ｒｎａを編集する方法
JP2025094806A Pending JP2025120313A (ja) 2020-03-31 2025-06-06 標的ｒｎａを編集する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2024065910A Active JP7698351B2 (ja) 2020-03-31 2024-04-16 標的ｒｎａを編集する方法
JP2025073407A Active JP7698371B1 (ja) 2020-03-31 2025-04-25 標的ｒｎａを編集する方法
JP2025094806A Pending JP2025120313A (ja) 2020-03-31 2025-06-06 標的ｒｎａを編集する方法

Country Status (11)

Country Link
US (1) US20230125942A1 (https=)
EP (1) EP4130274A4 (https=)
JP (4) JP7668547B2 (https=)
KR (1) KR20220165747A (https=)
CN (1) CN115698296A (https=)
AU (1) AU2021248204A1 (https=)
BR (1) BR112022019571A2 (https=)
CA (1) CA3179365A1 (https=)
IL (1) IL296955A (https=)
TW (1) TWI899197B (https=)
WO (1) WO2021201198A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3216313A1 (en) * 2021-04-30 2022-11-03 Masayuki NAKAMORI Myotonic dystrophy type 1 therapeutic drug
US20250302993A1 (en) * 2021-12-24 2025-10-02 GeCoRT Co., Ltd. Enzyme, complex, recombinant vector, therapeutic agent for genetic disorder, and polynucleotide
WO2024249445A2 (en) * 2023-05-26 2024-12-05 The Trustees Of Columbia University In The City Of New York An rna recognition and editing code of pentatricopeptide repeat proteins
CN117384884B (zh) * 2023-11-30 2024-03-08 辉大(上海)生物科技有限公司 IscB多肽及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336332A3 (en) * 2008-04-29 2011-11-09 Monsanto Technology LLC Genes and uses for plant enhancement
WO2013058404A1 (ja) * 2011-10-21 2013-04-25 国立大学法人九州大学 Pprモチーフを利用したrna結合性蛋白質の設計方法及びその利用
KR102893770B1 (ko) 2013-04-22 2025-11-28 고쿠리쓰다이가쿠호진 규슈다이가쿠 피피알 단백질을 이용하는 dna 결합성 단백질 및 그의 이용

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COMMUNICATION BIOLOGY, 2019, 発行日, Vol.2, No.85, p.1-8
DATABASE Genbank, accession no.EFJ215522, entry version 1 [online], 2016年06月25日, 掲載日, [2023年6月30日検索], http://www.ncbi.nlm.nih.gov/protein/EFJ21522.1/
DATABASE GenBank, accession no.EU495537, entry version 1 [online], 2016年06月26日, 発行日, [2023年6月30日検索], http://www.ncbi.nlm.nih.gov/nuccore/EU495537.1/
New Phytologist, 米国, 2019年10月31日, 掲載日, Vol.225, Issue 5, pp.1974-1992, https://doi.org/10.1111/nph.16297

Also Published As

Publication number Publication date
CN115698296A (zh) 2023-02-03
US20230125942A1 (en) 2023-04-27
JP2025120313A (ja) 2025-08-15
CA3179365A1 (en) 2021-10-07
WO2021201198A1 (ja) 2021-10-07
JP7698351B2 (ja) 2025-06-25
BR112022019571A2 (pt) 2022-12-06
EP4130274A4 (en) 2024-05-22
IL296955A (en) 2022-12-01
EP4130274A1 (en) 2023-02-08
JP7698371B1 (ja) 2025-06-25
JP2025107239A (ja) 2025-07-17
TW202204382A (zh) 2022-02-01
JP2024096897A (ja) 2024-07-17
KR20220165747A (ko) 2022-12-15
JPWO2021201198A1 (https=) 2021-10-07
TWI899197B (zh) 2025-10-01
AU2021248204A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
JP7698371B1 (ja) 標的ｒｎａを編集する方法
CN108690139B (zh) 新型融合蛋白的制备及其在提高蛋白质合成的应用
WO2023169410A1 (zh) 胞嘧啶脱氨酶及其在碱基编辑中的用途
CN110551700B (zh) Adh蛋白家族突变体及其应用
US20230076421A1 (en) Methods and compositions for manufacturing polynucleotides
CN111778169A (zh) 一种提高体外蛋白合成效率的方法
CN114381416B (zh) 一种高产5-氨基乙酰丙酸的重组大肠杆菌菌株及其应用
CN114686456B (zh) 基于双分子脱氨酶互补的碱基编辑系统及其应用
CN109152808A (zh) 用于核酸序列的特异性靶向的二聚蛋白质
RU2858663C2 (ru) Способ редактирования рнк-мишени
CN119591727A (zh) 优化的qbe碱基编辑系统及其应用
HK40086250A (en) Method for editing target rna
HK40080660A (zh) 编辑靶标rna的方法
CN114456244B (zh) 基因OsR498G1018986900.01及其编码的蛋白在调控水稻垩白中的应用
Lannes et al. Zinc-finger BED domains drive the formation of the active Hermes transpososome by asymmetric DNA binding
CN116606874B (zh) 胱硫醚-β-合成酶的制备方法和应用
EP4689147A2 (en) Methods and compositions for nucleic acid synthesis
JP2018201508A (ja) グルタチオンストレス耐性酵母
US20180118799A1 (en) Cyclized cytokine and method for producing same
JP2006254780A (ja) テアニン合成酵素
CN116606874A (zh) 胱硫醚-β-合成酶的制备方法和应用
WO2026050362A1 (en) Genome editing using programmable unwinding-annealing helicase and related single-strand annealing proteins
WO2025213929A1 (zh) 一种工程化胞嘧啶脱氨酶及其制备方法和用途
Albuquerque Production and characterization of INTERLEUKIN-9 and its receptor
CN116355100A (zh) 一种碱基编辑器及其构建方法与应用

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20220920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220922

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20220922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230522

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240606

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240620

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250408

R150 Certificate of patent or registration of utility model

Ref document number: 7668547

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150